Most Recent Annual Report
2019 Annual Report and Form 10K

Order Free Hardcopy
You can request a free hardcopy of this report mailed to you by clicking the button below.
You can request a free hardcopy of this report mailed to you by clicking the button below.
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer.